Healthcare
Immunic, Inc.(IMUX)
Live Price
Offline$14.20
+0.00% today
1Y Change
+102.57%
Window
Jun 25, 2025 โ Jun 18, 2026
- Market Cap
- $90.00M
- Revenue Growth
- 0.0%
- EPS Growth
- +37.6%
- Dividend Yield
- 0.0%
Coverage: 247 bars ยท Jun 25, 2025 โ Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Immunic, Inc. (IMUX) is a Healthcare stock with a market cap of $90.00M and listed on NASDAQ. The stock last traded around $14.20 and up 102.6% across the available one-year price window (Jun 25, 2025 โ Jun 18, 2026). Baseline metrics include revenue growth of 0.0%, EPS growth of +37.6%, a dividend yield of 0.0%. What stands out right now is revenue 0.0%, EPS +37.6%, free cash flow -1.1% with operating margin 0.0% and ROIC 1693.4%. Stock Foundry combines IMUX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
0.0% vs +7.6% peer median
Operating Margin
Below sector median
0.0% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 21, 2026, but the surprise data is still limited.
The setup is mixed rather than one-directional
Revenue is 0.0% and EPS is +37.6%, while operating margin sits near 0.0%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged +11.7% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 21, 2026 | โ | +6.1% | +21.6% | โ |
2026 Feb 26, 2026 | -20.0% | +7.6% | +17.1% | +32.9% |
2025 Nov 13, 2025 | +27.8% | +9.3% | -3.5% | -12.8% |
Benchmark Edge
IMUX vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
IMUX
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
IMUX Max Drawdown
-54.46%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for IMUX and SPY.
Company Overview
Immunic, Inc.
NASDAQ Global Select
Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.
- Leadership
- Daniel Vitt
- IPO Date
- Apr 17, 2014
- Employees
- 91
- Street Address
- 1200 Avenue of the Americas
- Mailing
- New York City, NY, 10036
- Region
- New York City, NY, US
- Reporting Currency
- USD
- Investor Line
- 332 255 9818
- Last Updated
- Apr 30, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- โ
- Price/Book
- โ
Growth
- Revenue
- 0.0%
- EPS
- +37.6%
- Free Cash Flow
- -1.1%
Profitability
- Gross Margin
- 0.0%
- Operating Margin
- 0.0%
- Net Margin
- 0.0%
- ROE
- -1197.8%
- ROIC
- 1693.4%
Balance Sheet
- Debt/Equity
- โ
- Current Ratio
- 0.75
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.